Navigation Links
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
Date:5/10/2013

THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.  LX4211 is an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).

The pioneer phase of the study was designed to gain important initial information regarding the safety of co-administration of LX4211 with insulin in this, the first test of dual inhibition of SGLT1 and SGLT2 in patients with insulin-dependent type 1 diabetes.  The successful conclusion of the 28-day pioneer group enables the initiation of the placebo-controlled expansion phase of the study to commence in up to 30 patients with type 1 diabetes.  Based on the results observed in the pioneer group, Lexicon has identified the 400 mg once daily dose of LX4211 as the appropriate treatment for the expansion phase of the trial.

"This is a very important first step in the future development of LX4211 in type 1 diabetes," said Dr. Arthur Sands , president and chief executive officer of Lexicon. "The preliminary results are very encouraging and provide a strong rationale for moving into the expansion phase of the trial."

LX4211, a first-in-class dual inhibitor, reduces the amount of glucose that enters the bloodstream from the gastrointestinal (GI) tract by inhibiting SGLT1, the major transporter responsible for glucose absorption, and enhances glucose excretion in the urine by inhibiting SGLT2, the major transporter responsible for glucose reabsorption by the kidney. Lexicon has previously demonstrated that SGLT1 inhibition by LX4211 incre
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Institute for Clinical Research, Inc., a clinical research organization ... new textbook,  Translational Research Methods for Diabetes, Obesity and ... scientific publisher. The textbook is the first ... early phase clinical studies of new drugs for diabetes, ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Infectious Disease Diagnostics Market by Product, Application, Technology, ... to their offering. , The infectious disease ... 7.9% to reach $18,156.2 million by 2019 from $12,422.8 ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has ... Allergen Source, Product & by End User - Global Forecast ... The global allergy diagnostics market is valued at $1,228.58 million ... of 12.67%, to reach $2,230.72 million by 2019. Allergy diagnostics ...
Breaking Medicine Technology:New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... , PARSIPPANY, N.J., Oct. 29 Ferring Pharmaceuticals Inc. ... Associate Medical Director for Orthopaedics. Dr. Kovelman will ... sodium hyaluronate), a treatment for knee pain due to ... products. , "Dr. Kovelman is exceptionally well qualified to ...
... Cempra Pharmaceuticals today announced a presentation on its ... of America, 47th Annual Meeting, October 29 to November ... more than 25 other antibiotics was tested against 1,737 ... from medical centers in the U.S., Europe and Latin ...
Cached Medicine Technology:Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 2Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 3Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates 2
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... The most common indication worldwide for pediatric transplantation, biliary ... liver disease in newborns. Recently, Childrens Hospital of Pittsburgh ... children with biliary atresia face that lead to the ... of children undergoing their first liver transplant are diagnosed ...
... Washington University School of Medicine in St. Louis have ... proteins associated with the formation of actin networks, which ... to move is important to a broad range of ... disease-causing invaders and how metastasizing cancer cells migrate from ...
... What: , The AACR Annual Meeting features the ... cancer research. This years meeting focuses on ... pipeline, clinical trials, and new approaches to cancer ... of the meeting, the program schedule and related ...
... Workout ... Jude Children,s Research ... Hospital(R), FORT LAUDERDALE, Fla., Jan. 8 ... Ab Crunch Challenge,a fitness challenge that will benefit your waistline and is expected ...
... Pa., Jan. 8 Isolagen(TM), Inc. (Amex: ILE ... Declan Daly,Chief Executive Officer of Isolagen, will present at ... 2008 at 2:00 p.m.,(Pacific Time) / 11:00 a.m. (Eastern ... Francis Hotel in San Francisco, California., The presentation ...
... Top Five New York State Hospitals, ... (OTC Bulletin Board: GLOB), an international e-Health, ... Wyndgate,Technologies(R) division has signed a purchase agreement ... New York for its,advanced transfusion management software, ...
Cached Medicine News:Health News:Children's Hospital physicians publish review of transplant issues in patients with biliary atresia 2Health News:Insights into cell movement likely to aid immune study, cancer research 2Health News:Insights into cell movement likely to aid immune study, cancer research 3Health News:Get a Six Pack While Giving Back 2Health News:Get a Six Pack While Giving Back 3Health News:Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference 2Health News:Global Med Technologies(R) Adds Eighth SafeTrace Tx(R) Client in New York State 2Health News:Global Med Technologies(R) Adds Eighth SafeTrace Tx(R) Client in New York State 3
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Fome-Cuf® Oral/Nasal Wire Reinforced Endotracheal ... kit is packaged individually and includes ... Maintenance Device (CMD™), and 15 mm ... provides maximum patient safety by helping ...
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
... Ruschelit® PVC. 2 eyes, oral. Marked ... age. X-ray opaque line. Graduated. Single ... Designed to reduce kinking of the ... Thermosensitive Ruschelit® PVC adapts to the ...
Medicine Products: